NeuroTherapeutics Pharma
NeuroTherapeutics Pharma develops therapeutics for patients suffering from central nervous system disorders
About NeuroTherapeutics Pharma
NeuroTherapeutics Pharma (NTP) was a biopharmaceutical firm established in 2006, headquartered in Chicago, with a clear focus on the development of novel treatments for central nervous system (CNS) disorders. The company's strategic direction was shaped by a management team with considerable experience in CNS drug development, including key executives who previously held positions at Ovation Pharmaceuticals. This team collectively had a track record of filing over 15 Investigational New Drug (IND) applications and securing approval for eight New Drug Applications (NDAs).
The company's core business was centered on discovering and advancing a pipeline of proprietary molecules for conditions such as epilepsy, as well as neuropathic and acute pain. NTP's operational model involved conducting preclinical studies and advancing its lead compounds toward human clinical trials, with the ultimate goal of commercialization. The business strategy relied on securing funding from venture capital and strategic investors to finance these long and capital-intensive research and development cycles. NTP successfully raised a total of $55 million over three funding rounds, including a significant $43 million Series B in 2010 and a $12 million Series C in 2011. Key investors included prominent names such as SR One, MPM Capital, F-Prime Capital (Fidelity Biosciences), Novo Ventures, and Pfizer, among others.
NTP's primary asset was its lead compound, NTP-2014, which demonstrated promising efficacy in various preclinical models for epilepsy and pain. The compound was designed to work through a new mechanism of action, distinct from other marketed products, by targeting a novel molecular site to reduce aberrant excitatory discharges in the nervous system. Preclinical data suggested a favorable safety profile and superior performance compared to existing blockbuster drugs at the time. The plan was to advance NTP-2014 through multiple Phase II proof-of-concept trials. Despite its promising technology and substantial financial backing, NeuroTherapeutics Pharma eventually ceased operations and is now considered a deadpooled company.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2011 | $12M | $48M | Pfizer Ventures | — |
| SERIES BOther financing | May 2010 | $43M | $172M | GSK · F-Prime · SR One · MPM BioImpact | — |
Growth signals
Latest recorded traffic for NeuroTherapeutics Pharma is 0 monthly website visits, down 100% over the last three months. NeuroTherapeutics Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NeuroTherapeutics Pharma in the Chicago Heights ecosystem
The NeuroTherapeutics Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
SR One
MPM BioImpact
GSK
F-Prime
Novo Ventures
Series B and later1 investor entered at this stage
- PVPfizer Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroTherapeutics Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroTherapeutics Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










